StockWatch
·
AMANTA HEALTHCARE LTD · QQ2 FY-2027 · THE CALL

Strong Q2 delivery, FY27 guidance cut; SteriPort ramp-up on track

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsAMANTAAmanta Healthcare Ltd09 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade B

Hit Q2 targets on revenue & margin; FY27 full-year guidance cut 2–4% from prior ₹440 Cr to ₹420–430 Cr. SteriPort Line 3 slightly late (Sept vs 'late Aug').

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Amanta delivered a strong Q2 (17% revenue growth, 21.6% EBITDA margin, ₹4.9 Cr PAT despite polymer volatility). SteriPort Line 3 ramp-up is on track and should drive FY27 revenue of ₹420–430 Cr. However, this guidance was cut from the prior ~₹440 Cr target, and SVP facility execution (March 2027 completion, product commercialization Q1 FY28+) remains uncertain. Near-term catalysts are solid, but regulatory pricing pressure (NPPA/NLEM) and polymer cost volatility are material headwinds.

₹83.1 Cr

Revenue · +17.3% YoY

₹4.9 Cr

Reported PAT · +302.5% YoY

Expanding

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

Top line grew 17% YoY in Q2; revenue ₹83.1 Cr

MET

Delivered revenue ₹83.1 Cr, YoY +17.3%

PAT ₹4.86 Cr, up 26% YoY

MISS

Q2 PAT ₹4.9 Cr, YoY +302.5%; H1 PAT grew 12% YoY (confusion between Q2 vs H1 metrics)

EBITDA margin 21.6% in Q2, healthy despite polymer headwinds

MET

Delivered OPM 20.7%; EBITDA margin claim plausible but OPM slightly lower

FY27 revenue ₹420–430 Cr annualized

OVERSTATED

Prior guidance ~₹440 Cr (baseline ₹370 + Line 3 ₹70); new guidance ₹420–430 is 2–4.5% below prior

SteriPort Line 3 commissioned Sept 2026, at full capacity by Nov 20

MET

Call Nov 4; management stated 52–55% utilization 'as of call', 100% from Nov 20 — plausible ramp-up

Earnings quality

What changed since the last call

Deltas vs. the prior call

FY27 revenue guidance lowered

Downgrade

Prior: ~₹440 Cr (baseline ₹370 + Line 3 ₹70 for 7 mo); Current: ₹420–430 Cr annualized. Line 3 commissioning delayed by ~1 month.

SteriPort Line 3 timeline on track

Neutral

Expected ₹60 Cr in FY27 (pro-rata), ₹110 Cr annual run-rate once at full capacity. Confirmed 100% utilization by Nov 20.

Debt trajectory improved

Upgrade

Debt-to-equity 3.5x (FY23) → 1.1x (FY26). Expected to reach ₹130–150 Cr ex-WC by end FY27. Annual repayment ₹30–32 Cr.

Solar power operational

New

₹10.8 MW captive plant generating since Q1 FY27. ₹9 Cr annual power cost saving; structural EBITDA cushion.

SVP facility confirmation

Neutral

Expected March 2027 completion. 20-product inhalation pipeline; 2 products commercialized, 6 more in R&D. Execution risk remains.

The Q&A

Analysts pressed hard on margin sustainability (Chirayu asked gross-margin trajectory post-polymer normalization; mgmt deflected with 'Q3–Q4' timeline). Questions on SVP revenue (Vedant, Venant) met with cautious, speculative estimates. Mgmt defended against NPPA/NLEM regulatory risk but conceded distribution margins (not mfg) at risk. Overall: moderately tough session; mgmt held ground but lacked specifics on long-term assumptions.

The exchanges that mattered

SteriPort capacity & utilization — Divya, VKSPL

Answered

Overall plant ~95–97%; SteriPort Line 3 (commissioned Sept) ~55% capacity. 100% utilization from Nov 20 onwards, all lines combined.

SteriPort addressable market & share — Divya, VKSPL

Partial

IV fluid market ~₹190–200 Cr. SteriPort 6% market share alone (₹12 Cr capacity), BFS another 2.5–3%. Market share 'amorphous' because of market consolidation.

Gross margin outlook post-polymer normalization — Chirayu, Aarth Growth Fund

Partial

Polymer price normalized 3–6 months; margin expansion expected Q3–Q4 via product mix shift and continued cost realization. EBITDA already at 21.6% despite volatility.

SVP market strategy — Chirayu, Aarth Growth Fund

Answered

SVP for inhalation/ophthalmics. Marketed via 200–250 channel partners. ICU demand strong; SteriPort is ~10-yr track record, 35+ crore bottles sold. No fungal contamination complaints.

Debt repayment & balance sheet — Aniket Nikumb, ABN Capital

Answered

Sept-end borrowing ~₹190 Cr (incl ₹45 Cr WC). Ex-WC, ₹150 Cr. FY27 end: expect ₹130 Cr ex-WC + ₹50 Cr WC = ₹180 Cr. Annual repayment ₹30–32 Cr. By FY29 net debt ₹100 Cr + ₹50 Cr WC.

SVP product pipeline & regulatory approvals — Venkat Reddy, Mars Investments

Partial

20-product inhalation pipeline, 2 commercialized. SVP line cost ~₹120 Cr. Regulatory filings planned Jan–Feb FY28; approvals for advanced markets (Canada, Australia, EU) expected within 6 months of filing.

SVP capacity utilization & revenue ramp — Saket Saurabh, Sagari Capital

Dodged

Initial SVP utilization 45–50% in first 2 qtrs post-commission. Revenue still speculative; single inhalation product ~₹7–70 Cr potential (very uncertain). ₹16 Cr FY28 very conservative.

CMO/CDMO strategy — Saket Saurabh, Sagari Capital

Answered

Not a classic CMO/CDMO. Do develop & license products (e.g., ophthalmics). ~₹25–30 Cr revenue from licensing/contract manufacturing, ~2–3% of revenue. Inhalation & intensive care are in-house focus.

FY28 top-line and SVP contribution — Garvit Goyal, Serene Alpha

Partial

FY28 full-year ~₹420–430 Cr target (same annualized rate as FY27 Q3–Q4). SVP capex would cost ₹120 Cr. Post-SVP commission, CapEx shifts to automation, product development, R&D (₹7–8 Cr per year).

Regulatory (NPPA/NLEM) pricing risk — Venkat Reddy, Mars Investments

Answered

NPPA concerned with reducing distribution margin, not mfg margin. Amanta retail-dependent, so distribution margin (not mfg) at risk. Decent hedge available on market-facing side, but retail profitability impacted.

Guidance

Forward guidance and management's confidence

FY27 revenue ₹420–430 Cr annualized

Medium

Prior ~₹440 Cr (baseline ₹370 + Line 3 ₹70 for 7 mo); now lowered 2–4.5%. Based on Oct–Nov run-rate at SteriPort Line 3 55% utilization ramping to 100% by Nov 20.

FY28 revenue ~₹425 Cr (mentioned in prior call)

Low

SVP still under construction (March 2027); product commercialization post-Q1 FY28. Upside highly dependent on SVP ramp speed and inhalation product acceptance.

2-yr CAGR 20%+ revenue growth

Medium

Assumes FY27 ₹420–430 Cr → FY29 ~₹640+ Cr CAGR 20%+. SteriPort full-year contribution (~₹110 Cr) + SVP ramp (potential ₹50–100 Cr by FY29) + base growth ~10% underlying.

EBITDA margins 25%+ for 2-yr outlook

Medium

Q2 delivered 21.6% margin despite >70% polymer price hike. Guidance assumes polymer normalization in 3–6 mo, product mix improvement, and solar cost advantage (₹9 Cr/year).

SVP capex ~₹120 Cr (mostly committed)

High

Facility expansion for inhalation/ophthalmics. Completion March 2027. Post-SVP, capex shifts to automation, R&D (₹7–8 Cr/year).

Risks the call surfaced

Ranked by how much they should concern a holder

Commodity (polymer) price volatility

Medium

Polymer prices rose >70% linked to oil; currently volatile, mgmt expects normalization 3–6 mo. EBITDA margin already absorbed loss via product mix; limited hedge further.

Regulatory pricing (NPPA/NLEM)

Medium

NPPA/NLEM focused on reducing distribution margins, not mfg. But hospital-dependent revenue (retail outlet) will see profitability impact. Amanta exposed on retail side.

SVP execution & ramp-up risk

High

SVP facility completion March 2027, but product transfer from existing lines is 'speculative' & timeline uncertain (6–9 mo regulatory hurdle). Inhalation revenue unquantified; mgmt called it 'very speculative' (₹16 Cr FY28 floor).

FY27 revenue guidance miss

Medium

Prior FY27 guidance ~₹440 Cr (baseline ₹370 + Line 3 ₹70 for 7 mo); revised to ₹420–430 Cr. 2–4.5% miss due to SteriPort Line 3 commissioning delay (Sept vs expected 'late Aug').

Customer concentration

Low

SteriPort demand concentrated in ICU, critical care, high-dependency units. Hospital consolidation or shift to lower-value products could pressure volumes/pricing.

Management

Score 6/10. Transparent on challenges (polymer volatility, regulatory risk); evasive on specifics (SVP revenue, TAM, market-share assumptions). Mgmt acknowledged knowledge gaps ('I am not able to comprehend' to Divya on TAM). Some confusion between Q2 and H1 metrics (PAT growth). SteriPort Line 3 commissioned as planned (Sept, slight delay vs 'late Aug'). Solar project delivered (₹10.8 MW operational). Debt trajectory improved 3.5x → 1.1x. Track record solid on capital projects, less certain on product commercialization (SVP pipeline only 2 of 20 inhalation products live).

What to watch next
  • 1 · Nov 20, 2026

    SteriPort Line 3 reaches 100% utilization; capacity up ₹5 Cr annually

  • 2 · Q3–Q4 FY27

    SteriPort Line 3 full ramp; target ₹110 Cr annual revenue run-rate by March

  • 3 · Mar 31, 2027

    SVP facility construction complete; product transfer & trials underway

Near-term catalysts are solid, but regulatory pricing pressure (NPPA/NLEM) and polymer cost volatility are material headwinds.

Informational and educational content only. Not investment advice.